Antithrombotic treatment of atrial fibrillation in hospital;Antitrombotisk behandling av atrieflimmer i sykehus

Tidsskrift for den Norske Laegeforening

Volumn 121, Issue 24, 2001, Pages 2800-2804

  Thomassen, G ^a   Hansen, M S ^a   Nordoy A ^a   Hansen, J B ^a  

^a Medisinsk Avdeling   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN; FIBRINOLYTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOVERSION; CLINICAL PRACTICE; CONTROLLED STUDY; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HOSPITAL CARE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; STROKE; UNIVERSITY HOSPITAL; FEMALE; FIBRINOLYTIC THERAPY; MALE; MIDDLE AGED; NORWAY;

ADULT; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NORWAY; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY;

EID: 0035840787     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Atrial fibrillation as an independent risk factor for stroke: The Framingham study
2. Prevalence of atrial fibrillation in elderly subjects (The cardiovascular health study)
3. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications
4. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials
5. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial
6. Patients with nonvalvular atrial fibrillation at low risk of strke during treatment with aspirin: Stroke prevention in atrial fibrillation III study
7. Antithrombotic therapy in atrial fibrillation
8. Atrial fibrillation: A major contribution to stroke in the elderly. The Framingham study
9. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study
10. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation
11. Stroke prevention in atrial fibrillation study: Final results
12. Canadian atrial fibrillation anticoagulation (CAFA) study
13. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation
14. European atrial fibrillation trial: Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and a recent transient ischeaemic attack or minor ischaemic stroke
15. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study
16. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation
17. European stroke prevention study 2: Dipyridamole and acetylsalicylic acid in the prevention of stroke
18. Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation; Second Copenhagen atrial fibrillation, aspirin, and anticoagulation study (the AFASAK2 study)
19. Risk factors for intracranial hemorrhage in outpatients taking warfarin
20. Optimal oral anticoagulant therapy in patients with mechanical heart valves
21. Stroke prevention in atrial fibrillation II study
22. Atrial fibrillation: Current knowledge and recommendations for management
23. Treatment of atrial fibrillation in a district general hospital
24. Atrieflimmer - Epidemiologi, medikamentbruk og bivirkninger
25. Should all patients with atrial fibrillation receive warfarin?
26. The impact of long-term warfarin therapy on quality of life: Evidence from a randomized trial
27. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective
28. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community
29. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours
30. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation
31. Electrical reversion of cardiac arrhythmias
32. The management of chronic atrial fibrillation: Indications and method of conversion to sinus rhythm